Marker Therapeutics, Inc. (MRKR): Price and Financial Metrics
MRKR Price/Volume Stats
Current price | $4.32 | 52-week high | $9.68 |
Prev. close | $4.43 | 52-week low | $0.67 |
Day low | $4.27 | Volume | 9,000 |
Day high | $4.53 | Avg. volume | 20,508 |
50-day MA | $4.28 | Dividend yield | N/A |
200-day MA | $4.28 | Market Cap | 38.40M |
MRKR Stock Price Chart Interactive Chart >
MRKR POWR Grades
- MRKR scores best on the Growth dimension, with a Growth rank ahead of 82.91% of US stocks.
- The strongest trend for MRKR is in Stability, which has been heading up over the past 152 days.
- MRKR's current lowest rank is in the Momentum metric (where it is better than 4.96% of US stocks).
MRKR Stock Summary
- For MRKR, its debt to operating expenses ratio is greater than that reported by just 0.22% of US equities we're observing.
- With a year-over-year growth in debt of -100%, MARKER THERAPEUTICS INC's debt growth rate surpasses merely 0% of about US stocks.
- The volatility of MARKER THERAPEUTICS INC's share price is greater than that of 93.59% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to MARKER THERAPEUTICS INC are EQ, DTIL, CRIS, BCDA, and NVAX.
- MRKR's SEC filings can be seen here. And to visit MARKER THERAPEUTICS INC's official web site, go to www.markertherapeutics.com.
MRKR Valuation Summary
- In comparison to the median Healthcare stock, MRKR's EV/EBIT ratio is 123.29% lower, now standing at -3.4.
- Over the past 87 months, MRKR's price/earnings ratio has gone up 12.8.
Below are key valuation metrics over time for MRKR.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
MRKR | 2023-12-29 | 5.4 | 2.9 | -5.3 | -3.4 |
MRKR | 2023-12-28 | 5.6 | 3.1 | -5.5 | -3.6 |
MRKR | 2023-12-27 | 4.2 | 2.3 | -4.1 | -2.2 |
MRKR | 2023-12-26 | 4.0 | 2.2 | -3.9 | -2.0 |
MRKR | 2023-12-22 | 3.9 | 2.1 | -3.8 | -1.9 |
MRKR | 2023-12-21 | 3.9 | 2.1 | -3.8 | -1.9 |
MRKR Growth Metrics
- The 4 year price growth rate now stands at -38.77%.
- Its year over year cash and equivalents growth rate is now at -55.32%.
- Its 4 year net cashflow from operations growth rate is now at -143.34%.
The table below shows MRKR's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 6.946111 | -25.52485 | -35.8376 |
2022-06-30 | 2.99654 | -24.39446 | -41.34734 |
2022-03-31 | 2.206032 | -30.44557 | -43.00993 |
2021-12-31 | 1.24171 | -27.27977 | -41.87887 |
2021-09-30 | 0 | -28.64046 | -40.62278 |
2021-06-30 | 0 | -26.36428 | -35.56496 |
MRKR's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MRKR has a Quality Grade of D, ranking ahead of 10.32% of graded US stocks.
- MRKR's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- SIGA, TTNP, and PHIO are the stocks whose asset turnover ratios are most correlated with MRKR.
The table below shows MRKR's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.000 | NA | -1.190 |
2021-03-31 | 0.008 | 1 | -1.120 |
2020-12-31 | 0.010 | 1 | -1.458 |
2020-09-30 | 0.015 | 1 | -2.040 |
2020-06-30 | 0.014 | 1 | -4.245 |
2020-03-31 | 0.004 | 1 | -2127.159 |
MRKR Price Target
For more insight on analysts targets of MRKR, see our MRKR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $6.38 | Average Broker Recommendation | 1.38 (Strong Buy) |
Marker Therapeutics, Inc. (MRKR) Company Bio
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
Latest MRKR News From Around the Web
Below are the latest news stories about MARKER THERAPEUTICS INC that investors may wish to consider to help them evaluate MRKR as an investment opportunity.
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that the Company’s management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit. Both events will be held in-person and are scheduled alongside the J.P. Morgan 42 |
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseStudy participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and remains in complete response six months after MT-601 treatmentHOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported a clinical update on |
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesAnnounced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (zedenoleucel) for the treatment of patients with Acute Myeloid Leukemia (AML) Demonstrated enhanced anti-tumor activity in an aggressive, treatment-resistant AML cell line and provided an update on clinical readiness of the MT-401 Off-the-She |
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceHOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Pala |
MRKR Price Returns
1-mo | 5.62% |
3-mo | 12.21% |
6-mo | -15.63% |
1-year | 144.07% |
3-year | -82.15% |
5-year | -92.93% |
YTD | -21.45% |
2023 | 106.84% |
2022 | -72.02% |
2021 | -34.47% |
2020 | -49.65% |
2019 | -48.11% |
Loading social stream, please wait...